Scientific consultancy and contract research organization Broughton has announced a new inhalation testing service to help pharmaceutical companies bring oral and nasal pharmaceutical products to market.
The service builds on the company’s expertise in analytical testing and its understanding of aerosol and inhalation science, while giving customers the added benefit of working with a provider of testing, consulting and fully integrated compliance.
The inhalation testing service is aimed at pharmaceutical companies, generic drug manufacturers looking to reformulate existing products for inhalation devices and device manufacturers. It will focus on device formulation and testing for dry powder inhalers (DPIs), pressurized metered dose inhalers (pMDIs), soft mist inhalers (SMIs), nasal sprays, breath actuated devices and new inhaled devices . The new inhalation testing service includes early-stage production characterization and analysis, device selection and testing, small-scale manufacturing support and manufacturing scale-up. Customers will benefit from Broughton’s fully integrated service with access to analytical method development and validation, on-site stability storage, extractables and leachables (E&L) testing and toxicology support.
With their expert understanding of inhaled formulation systems and device compatibility, Broughton’s scientific experts have a proven track record in aerosol science, inhaler development, clinical program planning and execution, and successful regulatory submissions. The company has now expanded its operations to include technologies for pharmaceutical inhalation formulation testing and device verification.
Chris Allen, chief executive of Broughton, said: “Inhaled medicines can deliver faster effectiveness and at lower doses than other routes of drug delivery and offer a great opportunity to improve the quality of life for patients with respiratory disease. A In addition to treating the hundreds of millions of people with asthma and COPD worldwide, there are new applications for inhaled medications to explore. Interest in inhaled medications has soared since the pandemic, and many pharmaceutical companies are developing new products
“The development and commercialization of a new inhaled pharmaceutical product requires great energy and deep scientific understanding, which is a level of resource and subject matter expertise that is difficult to maintain in-house. Working with Broughton is like having the your own respiratory science team. We can apply our technical knowledge of inhalation devices, aerosolization and formulation science to give customers insight into how they can bring life-enhancing products to market efficiently and cost-effectively.” .
The service covers formulation characterization, pharmaceutical analysis and product characterization, inhalation device evaluation, selection and testing, and chemistry, manufacturing and control (CMC).
Source link
Ikaroa, a full-stack tech company, is proud to announce that Broughton launches its new inhalation testing service, which is designed to meet the demand for convenient, reliable testing for airborne pollutants. Combining cutting-edge technology with Broughton’s unique expertise, this revolutionary service allows customers to test for potentially hazardous air quality inside their homes and offices.
The automated inhalation test is based on advanced analytical techniques, providing high-precision results quickly and easily. The system allows users to determine the presence and concentration of potentially hazardous particles in the air, including dust, pollen, smoke and odors. In addition, users can monitor changes over time, providing valuable insight into the changes they may need to make in order to improve the air quality inside their homes.
With inhalation being a common cause of discomfort and illness, Broughton’s new testing service couldn’t have come at a better time. According to recent research, the number of people suffering from respiratory conditions is on the rise. The importance of testing and understanding the pollutants in the air we breathe has never been greater.
Ikaroa’s proprietary cloud-based platform is enabling the Broughton team to deliver on the promise of the service. With an intuitive user-experience, the combination of cutting-edge technology and Broughton’s expertise has allowed the project to be completed faster than originally estimated.
The inhalation testing service is now available throughout selected areas in the United Kingdom. With plans to expand the service to other countries, Broughton and Ikaroa continue to push boundaries, providing people with a comprehensive solution to improving the air quality of their homes.
